Phase III

17th May 2019

News from the ocrelizumab front

https://www.brainwork.md/content/uploads/2019/05/Brainwork-NewsOcrelizumab.jpg 3300 2200 Carlotta Foletti, PhD Carlotta Foletti, PhD https://secure.gravatar.com/avatar/c8bf2814aa3641344dd6e3b11325ad20?s=96&d=mm&r=g 17th May 2019 17th May 2019

In our ongoing coverage of the AAN Annual Meeting in Philadelphia, we are focusing on select posters reporting on studies of ocrelizumab, an intravenous humanised monoclonal antibody that selectively targets…

Carlotta Foletti, PhD
0
0

16th October 2018

Serum neurofilament light: A biomarker for disease activity in MS

https://www.brainwork.md/content/uploads/2018/10/MPR425-Brainwork-illustration-soluble-biomarkers-V00-03-20181012.jpg 1920 1080 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 16th October 2018 19th October 2018

How close are we to establishing a reliable liquid biomarker for detecting disease onset, progression and treatment response in multiple sclerosis? According to Dr Peter Calabresi (Johns Hopkins, USA) at…

Mea Holm, PhD
1
0

19th September 2018

Quarterly migraine injection approved in US

https://www.brainwork.md/content/uploads/2018/09/Brainwork-FDAApprovesMigraine.jpg 2885 1900 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 19th September 2018 19th September 2018

The US FDA has approved a new humanised monoclonal antibody for migraine prevention in adults. Fremanezumab-vfrm – under the brand name AJOVYTM (Teva Pharmaceuticals) – prevents the interaction between calcitonin…

Peter Stevenson, PhD
1
0

27th May 2018

FDA approves blockbuster migraine treatment

https://www.brainwork.md/content/uploads/2018/05/Brainwork-FDAApproves.jpg 1200 800 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 27th May 2018 13th July 2018

On May 17th, 2018, the US FDA approved Aimovig™ (erenumab) following successful phase III trials. Aimovig™, co-developed by Amgen and Novartis, is the first approved migraine treatment targeting the calcitonin gene…

Mea Holm, PhD
1
0

18th May 2018

First MS treatment approved for children & adolescents

https://www.brainwork.md/content/uploads/2018/05/Brainwork-MSAdolescents.jpg 1600 1067 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 18th May 2018 13th July 2018

The US Food and Drug Administration (FDA) has approved the use of fingolimod (Gilenya®, Novartis, Basel, Switzerland) for the treatment of paediatric patients aged 10 to 18 years with relapsing…

Peter Stevenson, PhD
0
0

30th April 2018

Solriamfetol improves wakefulness in narcolepsy patients

https://www.brainwork.md/content/uploads/2018/04/Brainwork-Solriamfetol.jpg 1920 1280 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 30th April 2018 13th July 2018

This year’s American Academy of Neurology (AAN) meeting featured results of a randomised, placebo-controlled phase III study evaluating the safety and efficacy of solriamfetol for the treatment of excessive sleepiness (ES) in…

Lutz Achtnichts, MD
0
1

26th April 2018

Promising new migraine treatment presented at AAN 2018

https://www.brainwork.md/content/uploads/2018/04/Brainwork-Erenumab.jpg 5184 3456 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 26th April 2018 13th July 2018

Migraine is consistently ranked among the top 20 most burdensome diseases worldwide. Until now, existing prophylactic therapies for episodic migraine consisted mostly of repurposed medications for other conditions. They are…

Lutz Achtnichts, MD
0
2

1st November 2017

ECTRIMS-ACTRIMS: A conversation with Prof. Till Sprenger

https://www.brainwork.md/content/themes/anemos/images/empty/thumbnail.jpg 150 150 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 1st November 2017 13th July 2018

I had the chance to meet up with Professor Sprenger at ECTRIMS-ACTRIMS in Paris last week. We discussed the TEMSO study, which has been evaluating the long-term treatment effect of teriflunomide…

Lutz Achtnichts, MD
0
0

30th October 2017

ECTRIMS-ACTRIMS: Phase III data EXPAND on siponimod for secondary progressive multiple sclerosis

https://www.brainwork.md/content/uploads/2017/10/MPR426-Brainwork-illustrations-articles-V00-02-20171027_brain.png 898 506 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 30th October 2017 13th July 2018

Data presented at the recent 7th joint ECTRIMS-ACTRIMS meeting in Paris delved deeper into the efficacy of siponimod in the treatment of secondary progressive MS (SPMS). As Robert Fox (Mellen…

Peter Stevenson, PhD
0
0

27th October 2017

ECTRIMS-ACTRIMS: OBOE study explores biomarkers of neurodegeneration and inflammation in multiple sclerosis

https://www.brainwork.md/content/uploads/2017/10/welcome-to-brainwork-ectrims-2017.jpg 1920 1080 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 27th October 2017 13th July 2018

The development and characterisation of biomarkers in multiple sclerosis (MS) could be a crucial step in understanding disease pathways, as well as the therapeutic mechanisms of disease-modifying treatments. So was…

Peter Stevenson, PhD
0
0

News from the ocrelizumab front

Serum neurofilament light: A biomarker for disease activity in MS

Quarterly migraine injection approved in US

FDA approves blockbuster migraine treatment

First MS treatment approved for children & adolescents

Solriamfetol improves wakefulness in narcolepsy patients

​Promising new migraine treatment presented at AAN 2018

ECTRIMS-ACTRIMS: A conversation with Prof. Till Sprenger

ECTRIMS-ACTRIMS: Phase III data EXPAND on siponimod for secondary progressive multiple sclerosis

ECTRIMS-ACTRIMS: OBOE study explores biomarkers of neurodegeneration and inflammation in multiple sclerosis

Promising new migraine treatment presented at AAN 2018